Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has made significant strides in developing innovative pain management solutions, particularly focusing on abuse-deterrent formulations. With a commitment to addressing the opioid crisis, Collegium has positioned itself as a pioneer in creating safer alternatives for patients. The company’s flagship product, Xtampza ER, is an extended-release formulation of oxycodone designed to reduce the potential for misuse. Collegium's unique approach to pain management, combined with its robust pipeline of products, underscores its dedication to improving patient outcomes. With a strong market presence and a focus on responsible prescribing, Collegium Pharmaceutical continues to achieve notable milestones in the evolving landscape of pain management therapies.
DitchCarbon Score
How does Collegium Pharmaceutical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Collegium Pharmaceutical, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Collegium Pharmaceutical, Inc.'s reported carbon emissions
Collegium Pharmaceutical, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may not have established formal climate commitments or reduction strategies at this time. As a result, there are no specific figures to report regarding their Scope 1, 2, or 3 emissions. Additionally, there are no initiatives linked to the Science Based Targets initiative (SBTi) or other climate pledges. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. However, without specific commitments or data, it is unclear how Collegium Pharmaceutical, Inc. aligns with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Collegium Pharmaceutical, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
